Trends in the treatment of acne vulgaris: Are measures being taken to avoid antimicrobial resistance?

Journal of Drugs in Dermatology

Volumn 9, Issue 5, 2010, Pages 519-524

  Kinney, Megan A ^a   Yentzer, Brad A ^a   Fleischer Jr , Alan B ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; BENZOYL PEROXIDE PLUS CLINDAMYCIN; ERYTHROMYCIN; ISOTRETINOIN; RETINOID; TETRACYCLINE; ANTIINFECTIVE AGENT; DERMATOLOGICAL AGENT;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; DATA BASE; DRUG USE; HUMAN; MONOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; CLINICAL PRACTICE; DRUG EFFECT; FACTUAL DATABASE; INTRADERMAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROPIONIBACTERIUM ACNES; UNITED STATES;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ANTI-BACTERIAL AGENTS; DATABASES, FACTUAL; DERMATOLOGIC AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PROPIONIBACTERIUM ACNES; UNITED STATES;

EID: 77953149618     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Leyden JJ. Antibiotic resistant acne. Cutis. 1976;17:593-596.
2. Oberemok SS, Shalita AR. Acne vulgaris, II: Treatment. Cutis. 2002;70:11111-11114.
3. Crawford WW, Crawford IP, Stoughton RB, Cornell RC. Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol. 1979;72:187-190. (Pubitemid 10146759)
4. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol. 2001;144:339-346. (Pubitemid 32178816)
5. Thevarajah S, Balkrishnan R, Camacho FT, et al. Trends in prescription of acne medication in the US: Shift from antibiotic to non-antibiotic treatment. J Dermatol Treat. 2005;16:224-228. (Pubitemid 41597535)
6. Gollnick HP, Finlay AY, Shear N. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008;9:279-284.
7. Yentzer BA, Alikhan A, Teuschler H, et al. An exploratory study of adherence to topical benzoyl peroxide in patients with acne vulgaris. J Am Acad Dermatol. 2009;60:879-880.
8. Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol. 1983;8:41-845.
9. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: A report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1-S37. (Pubitemid 36791495)
10. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60:S1-S50.
11. Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol. 1994;131:331-336. (Pubitemid 24290215)
12. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA. 2002;288:2868-2879. (Pubitemid 35425073)
13. Stephenson BJ, Rowe BH, Haynes RB, et al. The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA. 1993;269:2779-2781. (Pubitemid 23154254)
14. Lucero M, Bendeck S, Ramos-Ceballos F, et al. Language disparities between patients and dermatologists in describing acne lesions. J Am Acad Dermatol. 2007;56:268-273. (Pubitemid 46074255)
15. Koo J. How do you foster medication adherence for better acne vulgaris management? Skinmed. 2003;2:229-233.
16. Ross EV. Acne, lasers and light. Adv Dermatol. 2005;21:1-32.
17. Burkhart CN, Specht K, Neckers D. Synergistic activity of benzoyl peroxide and erythromycin. Skin Pharmacol Appl Skin Physiol. 2000;13:292-296. (Pubitemid 30666028)
18. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2:234-245.
19. Fleischer AB, Jr., Dinehart S, Stough D, Plott RT. Safety and efficacy of a new extended-release formulation of minocycline. Cutis. 2006;78:21-31. (Pubitemid 44720406)
20. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol. 2007;21:747-753. (Pubitemid 46939044)
21. Richter JR, Forstrom LR, Kiistala UO, Jung EG. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol. 1998;11:227-233. (Pubitemid 29010428)
22. Zouboulis CC, Derumeaux L, Decroix J, et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol. 2000;143:498-505.
23. Schlessinger J, Menter A, Gold M, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6:607-615.
24. Loesche C, Pernin C, Poncet M. Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol. 2008;18:524-526.
25. Scheinfeld N. Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne. Curr Opin Investig Drugs. 2009;10:474-481.
26. Piette WW, Taylor S, Pariser D, et al. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol. 2008;144:1564-1570.
27. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56:439-410.
28. Pickert A, Raimer S. An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009;10:1515-1521.
29. Schonfeld TL, Amoura NJ, Kratochvil CJ. iPLEDGE allegiance to the pill: Evaluation of year 1 of a birth defect prevention and monitoring system. J Law Med Ethics. 2009;37:104-117.
30. Akamatsu H, Nishijima S, Takahashi M, et al. Effects of subminimal inhibitory concentrations of erythromycin, tetracycline, clindamycin, and minocycline on the neutrophil chemotactic factor production in Propionibacterium acnes biotypes 1-5. J Dermatol. 1991;18:247-51.